Introduction
============

Non-celiac gluten sensitivity (NCGS) relates to one or more of a variety of immunological, morphological or symptomatic manifestations that are precipitated by the ingestion of gluten in people in whom celiac disease (CD) has been excluded.[@b1-jnm-20-236] Although there is no definitive serological marker to distinguish NCGS from other gluten-related disorders, this new entity may suggest a possible link between gluten and irritable bowel syndrome (IBS).[@b2-jnm-20-236] The interest of gluten in IBS patients started more than a decade ago. Sanders et al[@b3-jnm-20-236] showed that 66 out of 300 (22%) IBS patients defined by Rome II criteria had positive serology, but the majority of them (43/66) had normal duodenal biopsy. In the same year, Wahnschaffe U et al[@b4-jnm-20-236] reported that 30% had increased celiac antibodies in duodenal aspirate and 23% with increased intra-epithelial lymphocyte (IEL) counts among 102 IBS patients, but only 9% having both. In a recent meta-analysis, the prevalence of biopsy-proven CD in patients fulfilling IBS criteria was 4.1% in a pooled data of 1,464 individuals,[@b5-jnm-20-236] which showed that some patients who initially presented with IBS-like symptoms should have been re-categorized as CD. However, there was a subset of patients without CD who developed gastrointestinal symptoms after gluten ingestion.[@b6-jnm-20-236]

Classically CD is diagnosed in a patient with diarrhea and malabsorption, in the presence of intestinal villous atrophy and positivity for gluten related antibodies, who demonstrates rapid clinical and histological response to a gluten free diet. CD is uncommon among Asians, and is particularly rare in people of Chinese ethnic origin. A recent systematic review of celiac disease identified only 18 Chinese patients with biopsy-proven CD.[@b7-jnm-20-236] Studies of Indian populations reported increasing incidence of celiac disease in recent years.[@b8-jnm-20-236],[@b9-jnm-20-236] One study from UK even showed that a particular Indian clan had a higher incidence of celiac disease than Europeans from the same area.[@b10-jnm-20-236] On the other hand, a few studies from China reported the presence of possible CD among IBS patients, but the incidences were low, and not all of them were histologically confirmed.[@b11-jnm-20-236],[@b12-jnm-20-236]

As far as we know, there are no reports for the other major ethnic groups in Southeast Asia regarding the prevalence of CD or NCGS. We wish to assess the prevalence of anti-deamidated gliadin peptide IgA antibodies (IgA DGP) in Asian patients fulfilling IBS criteria, which may shed some light on the clinical and immunological responses to gluten in this population.

Materials and Methods
=====================

We explored this association by retrospectively studying a cohort of ethnic Asian patients with IBS defined by Rome III criteria, who presented to a single private gastroenterology center in Singapore from year 2007 to 2012. We included all patients of Asian ethnicity who presented with IBS symptoms to the clinic, and excluded those without IBS and without anti-DGP testing as this was a retrospective review. Seventeen non-residents from Indonesia and 21 Indian expatriates working in Singapore were included in this cohort. All patients were tested for IgA DGP and IgA anti-endomysial antibody serology by the indirect immunofluorescence test method (IIFT-Mosaik: Gliadin (GAF-3X)/Intestine (Monkey), EUROIMMUN). The GAF-3X gliadin used is a repetitive gliadin-analogue fusion peptide consisting of an immunologically dominant deamidated epitope of gliadin with a length of nine amino acids. The patients also underwent gastroscopy, urease test for *Helicobacter pylori* and duodenal biopsies. Patients who were IgA DGP or IgA anti-endomysium antibody positive were advised to abstain from gluten-containing food. Information on demographics, presenting symptoms and response to gluten-free diet were extracted from case records. In addition, patients of Chinese ethnicity with positive serology were recalled for further testing of human leucocyte antigen (HLA)-DQ2 and HLA-DQ8. All data were analysed using statistical software SPSS Statistics Version 10 (SPSS Inc., Chicago, IL, USA).

As this was a retrospective review of patient records, approval was sought and given by the hospital's institution review board (vide PIEC/2013/016) to collate the data in an anonymous method.

Results
=======

Of 186 Asian patients included in this study, 34 (18%) were tested positive for IgA DGP but only one of them was also tested positive for IgA EMA. None of them had diabetes mellitus. Most patients, whether IgA DGP positive or negative, presented with bloating (74%), abdominal pain (65%), belching (62%), diarrhea (47%), flatulence (44%) and constipation (29%) ([Table](#t1-jnm-20-236){ref-type="table"}). IgA DGP positive patients were less likely to present with abdominal pain or flatulence compared to IgA DGP negative individuals.

The most bothersome symptoms for IgA DGP positive patients were mainly abdominal pain and diarrhea. There is a trend for IgA DGP positive patients to identify diarrhea as the most bothersome symptoms compared to IgA DGP negative patients, while other symptoms are not significantly different between the 2 groups.

In total, 24 patients (13%) demonstrated a low grade increase in IEL counts (defined as \> 10 but \< 40 intraepithelial lymphocytes per 100 enterocytes, Marsh 0) in their duodenal biopsies. IgA DGP positive patients were more likely to have increased IEL (10/34 = 29%) compared to IgA DGP negative patients (14/152 = 9%, *P* = 0.001). Villous blunting (defined as shortened villi without decrease in villous to crypt ratio) was common in IgA DGP positive patients compared to those who were IgA DGP negative, although the difference just failed to reach statistical significance (15/34 = 44% versus 42/152 = 27.6%, *P* = 0.059) ([Table](#t1-jnm-20-236){ref-type="table"}). None of these patients had more than Marsh 0 on histology.

Only one patient met the criteria for celiac disease. This was a 26-year-old expatriate from India who presented with bloating associated with loose stools, who had been diagnosed with IBS 2 years ago. There had been no weight loss. Full blood count, erythrocyte sedimentation rate, C-reactive protein, serum vitamin B12, folate and ferritin levels were all normal while IgA DGP and IgA EMA were positive. Duodenal biopsies showed mild intra-epithelial lymphocytosis more than 10 but no greater than 40 per 100 enterocytes, and only villi blunting not amounting to partial villous atrophy. Six months after starting on gluten free diet, his IgA EMA became negative, but IgA DGP remained positive. Nine months later both IgA EMA and IgA DGP were negative, and repeat duodenal biopsies did not reveal any lymphocytosis or villous blunting.

The prevalence of *H. pylori* infection in IgA DGP positive and IgA DGP negative groups was similar, at 17.6% and 30.9% respectively. Of the 6 IgA DGP positive patients who were *H. pylori* positive, one had villous blunting and another had increased IEL counts on duodenal biopsy. Of the 47 IgA DGP negative patients who were *H. pylori* positive, 13 had villous blunting, 3 had increased IEL and 4 had both changes on duodenal biopsy. The presence of *H. pylori* did not correlate to increased IEL counts (*P* = 0.468) in either group.

There were 124 Chinese patients including 8 Indonesian Chinese in this cohort. Their demographics were not different from the other patients. Twenty-one (17%) were positive for IgA DGP. Among 9 of the 21 IgA DGP positive Chinese patients who underwent HLA-DQ2/DQ8 genotyping, 2 patients were tested positive for HLA-DQ8. These 2 patients were sisters whose parents had emigrated from northern China where the traditional dietary staple was wheat. Neither of them had villous blunting, but one had increased IEL. The ancestry of the other 7 patients who were HLA-DQ2/DQ8 genotype negative was traced to southern China where the traditional staple diet is rice; one of the patients had concurrent systemic lupus erythematosus. Five of these 7 patients had villous blunting, and 2 had increased IEL.

Discussion
==========

CD was rarely reported in non-Indian Asian populations and gluten related disorders have not to date been recognized as a significant clinical problem.[@b11-jnm-20-236],[@b12-jnm-20-236] While classical CD is diagnosed on the basis of typical symptoms of malabsorption, positive serology with histological findings of villous atrophy or IEL \> 40/100 enterocytes,[@b1-jnm-20-236] the new entity of non-celiac gluten sensitivity has recently been described. Recent consensus proposed that definitions of NCGS are cases with negative anti-EMA and/or anti-tissue transglutaminase (tTG), normal duodenal histopathology and with the possible presence of biomarkers of native gluten immune-reaction such as anti-gliadin antibodies (AGA).[@b13-jnm-20-236]

Gliadin is a component of gluten, which plays an important part in the immunogenicity of gluten in CD. The dominant epitope responsible for the T-cell response appeared to be a deamidated glutamine residue of gliadin. Gluten refers to the complex of water insoluble proteins from wheat, rye and barley. It is poorly digested in the human intestine with or without CD, and crosses intactly into the submucosa of the small intestine. The gluten peptide is then deamidated in the submucosa by tTG. Deamidation enhances binding to HLA-DQ2 and HLA-DQ8 in susceptible individuals, and subsequently triggers inflammatory responses.[@b1-jnm-20-236],[@b14-jnm-20-236]--[@b15-jnm-20-236] Gliadin also contains peptides that are able to activate an innate immune response, in particular, inducing a selective expansion of IEL.[@b16-jnm-20-236] More IgA DGP positive patients had increased IEL counts (*P* = 0.001). We speculate that DGP provokes a milder form of inflammatory process in our study population, with normal or minimal changes in enterocyte architecture and less pronounced IEL. This inflammatory process then manifests clinically as IBS symptoms predominantly with diarrhea, which was identified as most bothersome symptom in IgA DGP positive IBS patients.

The original IgA AGA test has a low diagnostic accuracy and is therefore no longer recommended for initial diagnostic screening for CD.[@b17-jnm-20-236] The new synthetic IgA DGP used in our study has a higher sensitivity and is comparable to IgA anti-tTG.[@b18-jnm-20-236] Indeed, a recent study has shown that the sensitivity of IgA DGP was superior to anti-tTG and comparable to EMA in early-stage celiac disease with normal villous morphology.[@b19-jnm-20-236] On the other hand, IgG AGA was present in more than half of patients with NCGS, with a few patients having IgA AGA or IgG DGP.[@b20-jnm-20-236] In the same study, there was good congruence among IgG DGP, IgA EMA and IgA tTG for CD. This is similar to the findings reported by Adler et al[@b21-jnm-20-236] and Carroccio et al.[@b22-jnm-20-236] Close to half of their patients with gluten sensitivity were positive for either IgG and/or IgA AGA, but only a few of them were EMA positive, showing only mild changes on wireless capsule endoscopy, and these patients were deemed not to have CD.[@b21-jnm-20-236],[@b22-jnm-20-236] Eighteen percent of our patients were IgA DGP positive among whom all but one were IgA EMA negative, and less than half had villous blunting. In addition, one of our patients with positive IgA DGP was diagnosed with systemic lupus erythematosus, suggesting an autoimmune diathesis. More studies are needed to explore the significance of isolated IgA DGP positivity in NCGS, and determine whether it is a transient immune response to gluten challenge.

The prevalence of HLA-DQ2 and HLA-DQ8 in Southeast Asia is unclear. The frequency of HLA-DQ2 is high in northern China along the Silk Route, where the consumption of wheat is higher than in the south. In Jiangsu Province, along Yangtze River, the frequency of HLA-DQ2 is 7.2% and the frequency of HLA-DQ8 is 4.7%.[@b23-jnm-20-236],[@b24-jnm-20-236] There is an association of HLA-DQ2 with gluten sensitivity, although this is weaker than its linkage with CD. HLA-DQ2 in NCGS may be related to presence of biomarkers of innate gluten reaction such as AGA. It has been suggested that this newly recognized and incompletely understood entity of gluten sensitivity is part of the spectrum of gluten related disorders.[@b3-jnm-20-236],[@b25-jnm-20-236] In a prospective gluten challenge study, the prevalence of HLA-DQ2 or DQ8 was 53% in the NCGS group and 100% in the CD group.[@b21-jnm-20-236] The low prevalence of HLA-DQ8 and absence of HLA-DQ2 in our patients confirm that our population has a low genetic susceptibility to CD, yet there is significant gluten sensitivity, suggesting that dietary rather than genetic factors are relevant in the emergence of NCGS in this part of the world.

Increased IEL can be a non-specific finding associated with many non-CD causes such as drugs, infection, immune dysregulation, inflammatory bowel disease, microscopic colitis, sarcoidosis and IgA deficiency. It was shown that there may be an association with IBS in those cases with no apparent causes identified, and the IEL count becomes normal on repeat biopsy in 76%.[@b26-jnm-20-236] In our study, histopathology findings were close to normal with findings of only villous blunting and increased IEL of more than 10 but less than 40 enterocytes - no more that Marsh Grade 0, suggesting the possibility of immune responses to gluten not amounting to CD. The presence of *H. pylori* did not appear to affect the IEL counts in both IgA DGP positive and negative groups.

Our study has a few limitations. Firstly, only IgA DGP and IgA EMA but not IgA tTG, were tested. Future studies may include all three serologic markers to compare their sensitivity and specificity in diagnosing NCGS. Furthermore only patients with positive IgA DGP were advised to go on GFD so the response to GFD in IgA DGP negative cases is not known. As our study is a retrospective review of clinical notes, detailed health history and food gradient were not available. Lastly, no repeat serological tests and duodenal biopsies were done to assess response to GFD, and to determine whether the positive serology is a transient immune response to gluten.

In conclusion, we have described a series of Asian, mainly Chinese, patients with IBS by Rome III criteria who have serological markers and changes in duodenal biopsies that would be consistent with non-celiac gluten sensitivity. This is novel as this entity has not to our knowledge been reported in the Asian literature. As this was a clinical observation study, prospective studies are required to verify the association of IBS with NCGS in Asian populations.
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###### 

Comparison of Demographics, Symptomatology, Endoscopic and Histological Findings Between Anti-deamidated Gliadin Peptide IgA Positive and Negative Irritable Bowel Syndrome Patients

                                                    IgA DGP (+) (n = 34)                                IgA DGP (--) (n = 152)                                *P*-value
  ------------------------------------------------- --------------------------------------------------- ----------------------------------------------------- -----------
  Age (mean \[SD\], yr)                             42.5 (10.8)                                         43.0 (12.9)                                           0.589
  Female (n \[%\])                                  24 (71)                                             75 (49)                                               0.025
  Male:Female                                       10:24                                               77:75                                                 
  Prevalence of IgA DGP by ethnic group (n \[%\])                                                                                                             
    Chinese (n = 124)                               21 (17)                                             103 (83)                                              0.548
    Indonesian (n = 17)                             7 (41)                                              10 (59)                                               0.018
    Indian (n = 37)                                 5 (14)                                              32 (86)                                               0.483
    Eurasian (n = 5)                                1 (20)                                              4 (80)                                                1.000
    Others (n = 3)                                  0 (0)                                               3 (100)[^a^](#tfn1-jnm-20-236){ref-type="table-fn"}   \-
  Symptoms at presentation (n \[%\])                                                                                                                          
    Abdominal pain                                  22 (65)                                             125 (82)                                              0.023
    Bloating                                        25 (74)                                             125 (82)                                              0.245
    Constipation                                    10 (29)                                             45 (30)                                               0.982
    Diarrhea                                        16 (47)                                             70 (46)                                               0.915
    Belching                                        21 (62)                                             85 (56)                                               0.534
    Flatulence                                      15 (44)                                             107 (70)                                              0.004
    Vomiting                                        1 (3)                                               2 (1)                                                 0.496
  Most bothersome symptom (n \[%\])                                                                                                                           
    Abdominal pain                                  10 (29)                                             62 (41)                                               0.25
    Bloating                                        7 (21)                                              46 (30)                                               0.30
    Constipation                                    2 (6)                                               7 (5)                                                 0.67
    Diarrhea                                        10 (29)                                             19 (12)                                               0.02
    Belching                                        2 (6)                                               7 (5)                                                 0.67
    Flatulence                                      2 (6)                                               8 (5)                                                 1.00
    Other symptoms                                  1 (3)[^b^](#tfn2-jnm-20-236){ref-type="table-fn"}   3 (2)[^c^](#tfn3-jnm-20-236){ref-type="table-fn"}     NA
  Endoscopic and histological findings (n \[%\])                                                                                                              
    *H. pylori* (+)                                 6 (18)                                              47 (31)                                               0.112
    Villous blunting                                15 (44)                                             42 (28)                                               0.059
    IEL                                             10 (29)                                             14 (9)                                                0.001

These 3 patients are Japanese, Korean and Vietnamese, respectively;

Choking sensation;

Nausea, loss of weight and headache, respectively.

IgA DGP, anti-deamidated gliadin peptide IgA antibodies; IEL, intra-epithelial lymphocytosis; NA, not applicable.

Villous blunting = villous to crypt ratio of \< 3:1. Intra-epithelial lymphocytosis = more than 10 lymphocytes per 100 enterocytes.

All *P*-values were calculated using Fisher's exact test.
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